~~<i id='0B2D551F2A'><strike id='0B2D551F2A'><tt id='0B2D551F2A'><pre id='0B2D551F2A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：leisure time 2025-10-02 05:54:39 - browse：8

It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Do digital therapeutics have a future in medicine?

explore

entertainment

Wikipedia

hotspot

explore

AdobeUltimaGenomics,anupstartsomeobservershavecalleda“darkhorse”intheworldofDNAsequencing,willsoonla

WSS

My chronic pain journey would have been easier knowing 5 things % STAT

Men with early prostate cancer can safely opt out of treatment

Transgender women dream of pregnancy via uterus transplants

Doctors have an ethical obligation to be advocates

Doctors have an ethical obligation to be advocates

FDA approves first blood sugar monitor without finger pricks

explore

comprehensive

explore

Bright Health sells Medicare Advantage business to Molina

Burning questions about Delta and the next phase of the Covid pandemic

Virginia high school admissions case could be legal follow

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

George Santos makes 1st court appearance after pleading not guilty to 13 counts

General Catalyst, Summa Health deal will turn on physician buy

Alkermes shareholders re

Time to name cancers by genetics, not organ of origin, expert says

Dobbs anniversary: the lost opportunity of abortion as health care

Transgender women dream of pregnancy via uterus transplants

explore

Juul spent big to court Black leaders to promote its e

The response to Covid

Burning questions about Delta and the next phase of the Covid pandemic

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Time to name cancers by genetics, not organ of origin, expert says

Biden administration opens offers in Medicare drug price negotiations

entertainment

Wikipedia

hotspot

explore